2022 COLLECTION TYPE:
MIPS CLINICAL QUALITY MEASURES (CQMS)

MEASURE TYPE:
Process

DESCRIPTION:
The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period

INSTRUCTIONS:
This measure is to be submitted a minimum of **once per performance period** for all patients with diabetes mellitus seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

**NOTE:** Patient encounters for this measure conducted via telehealth (e.g., encounters coded with GQ, GT, 95, or POS 02 modifiers) are allowable.

Measure Submission Type:
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

DENOMINATOR:
Patients 18 - 75 years of age with diabetes with a visit during the measurement period

**DENOMINATOR NOTE:** To assess the age for exclusions, the patient's age at the end of the measurement period should be used.

*Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

Denominator Criteria (Eligible Cases):
Patients aged 18 years to 75 years on date of encounter

AND

AND
Patient encounter during the performance period (CPT or HCPCS): 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99385*, 99386*, 99387*, 99395*, 99396*, 99397*, G0438, G0439
AND NOT
DENOMINATOR EXCLUSIONS:
Patients who use hospice services any time during the measurement period: G9715
OR
Patients who use palliative care services any time during the measurement period: G9995
OR
Patient age 66 or older in Institutional Special Needs Plans (SNP) or residing in long-term care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period: G2108
OR
Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period AND a dispensed medication for dementia during the measurement period or the year prior to the measurement period: G2109
OR
Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period: G2110

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>Donepezil</td>
</tr>
<tr>
<td></td>
<td>Galantamine</td>
</tr>
<tr>
<td></td>
<td>Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>Memantine</td>
</tr>
</tbody>
</table>

Table: Dementia Exclusion Medications

Patients with a screening for nephropathy or evidence of nephropathy during the measurement period

K74.02, K74.1, K74.2, K74.4, K74.5, K74.60, K74.69, N18.5, N18.6
J96.91, J96.92, J98.2, J98.3, K70.10, K70.11, K70.2, K70.30, K70.31, K70.40, K70.41, K70.9, K74.0, K74.00, K74.01,
K74.02, K74.1, K74.2, K74.4, K74.5, K74.60, K74.69, N18.5, N18.6

OR

Positive microalbuminuria test result documented and

-Codes to identify Advanced Illness: A81.00, A81.01, A81.09, C25.00, C25.01, C25.02, C25.3, C25.4, C25.7, C25.8,
C25.9, C71.0, C71.1, C71.2, C71.3, C71.4, C71.5, C71.6, C71.7, C71.8, C71.9, C77.0, C77.1, C77.2, C77.3, C77.4,
C77.5, C77.6, C78.0, C78.1, C78.2, C78.30, C78.39, C78.4, C78.5, C78.6, C78.7, C78.8, C78.9, C79.0, C79.01, C79.02,
C79.10, C79.11, C79.19, C79.2, C79.31, C79.32, C79.40, C79.49, C79.51, C79.52, C79.60, C79.61, C79.62, C79.70,
C79.71, C79.72, C79.81, C79.82, C79.89, C79.9, C91.00, C91.02, C92.00, C92.02, C93.00, C93.02, C93.90, C93.92,
C93.Z0, C93.Z2, C94.30, C94.32, F01.50, F01.51, F02.80, F02.81, F03.90, F03.91,

NUMERATOR:

Patients with a screening for nephropathy or evidence of nephropathy during the measurement period

- Numerator Instructions:
  This measure is looking for a nephropathy screening test or evidence of nephropathy.

- Numerator Options:
  Performance Met:
  Positive microalbuminuria test result documented and reviewed (3060F)

OR
Performance Met: Negative microalbuminuria test result documented and reviewed (3061F)

OR
Performance Met: Positive macroalbuminuria test result documented and reviewed (3062F)

OR
Performance Met: Documentation of treatment for nephropathy (e.g., patient receiving dialysis, patient being treated for ESRD, CRF, ARF, or renal insufficiency, any visit to a nephrologist) (3066F)

OR
Performance Met: Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy (G8506)

OR
Performance Not Met: Nephropathy screening was not performed, reason not otherwise specified (3060F or 3061F or 3062F with 8P)

RATIONALE:
Diabetes is the seventh leading cause of death in the United States. In 2017, diabetes affected approximately 34 million Americans (10.5 percent of the U.S. population) and killed approximately 84,000 people (CDC, 2020a). Diabetes is a long-lasting disease marked by high blood glucose levels, resulting from the body’s inability to produce or use insulin properly (CDC, 2020b). People with diabetes are at increased risk of serious health complications including vision loss, heart disease, stroke, kidney damage, and amputation of feet or legs (CDC, 2018).

In 2017, diabetes cost the U.S. an estimated $327 billion: $237 billion in direct medical costs and $90 billion in reduced productivity. This is a 34 percent increase from the estimated $245 billion spent on diabetes in 2012 (American Diabetes Association [ADA], 2018).

High blood sugar levels in patients with diabetes put them at a higher risk of damaging their kidneys and causing kidney disease (ADA, 2020a). Kidney disease is one of the most common adverse outcomes of diabetes, affecting 20-40 percent of patients with diabetes. Kidney Disease can lead to kidney failure and is the leading cause of end stage renal disease (ESRD) (ADA, 2020b). In 2013, there were more than 51,000 new cases of kidney failure among people with diabetes (National Kidney Foundation, 2016). In 2014, diabetes accounted for 44% of 118,000 new cases of ESRD (United States Renal Data System, 2016).

CLINICAL RECOMMENDATION STATEMENTS:
American Diabetes Association (2020):
Screening
- At least once a year, assess urinary albumin (e.g., spot urinary albumin-to-creatinine ratio [UACR]) and estimated glomerular filtration rate (eGFR) in patients with type 1 diabetes with duration of >=5 years, and in all patients with type 2 diabetes, regardless of treatment. (Level of evidence: B)
- Patients with urinary albumin >30 mg/g creatinine and/or an eGFR <60 mL/min/1.73m2 should be monitored twice annually to guide therapy. (Level of evidence: C)

Treatment
- An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) is not recommended for the primary prevention of chronic kidney disease in patients with diabetes who have normal blood pressure, normal UACR (<30 mg/g creatinine), and normal estimated glomerular filtration rate. (Level of evidence: B)
- In nonpregnant patients with diabetes and hypertension, either an ACE inhibitor or ARB is recommended for those with modestly elevated UACR (30-299 mg/g creatinine) (Level of evidence: B) and is strongly recommended for those with UACR >=300 mg/g creatinine and/or eGFR < 60 mL/min/1.73.m2. (Level of evidence: A)
- Periodically monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium when ACE inhibitors, ARB, or diuretics are used. (Level of evidence: B)
- Patients should be referred for evaluation by a nephrologist if they have an estimated GFR<30 mL/min/1.73 m². (Level of evidence: A)
- Promptly refer to a physician experienced in the care of kidney disease for uncertainty about the etiology of kidney disease, difficult management issues, and rapidly progressing kidney disease. (Level of evidence: A)

American Association of Clinical Endocrinologists & American College of Endocrinology (2015):
- Beginning 5 years after diagnosis in patients with type 1 diabetes (if diagnosed before age 30) or at diagnosis in patients with type 2 diabetes and those with type 1 diabetes diagnosed after age 30, annual assessment of serum creatinine to determine the estimated glomerular filtration rate (eGFR) and urine albumin excretion rate (AER) should be performed to identify, stage, and monitor progression of diabetic nephropathy (Grade C; best evidence level 3).
- Patients with nephropathy should be counseled regarding the need for optimal glycemic control, blood pressure control, dyslipidemia control, and smoking cessation (Grade B; best evidence level 2).
- In addition, they should have routine monitoring of albuminuria, kidney function electrolytes, and lipids (Grade B; best evidence level 2).
- Associated conditions such as anemia and bone and mineral disorders should be assessed as kidney function declines (Grade D; best evidence level 4).
- Referral to a nephrologist is recommended well before the need for renal replacement therapy (Grade D; best evidence level 4).

COPYRIGHT:
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. NCQA makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on measures and specifications or data reflective of performance under such measures and specifications.

The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses or requests for alteration of the measures and specifications must be approved by NCQA and are subject to a license at the discretion of NCQA. NCQA is not responsible for any use of the Measures. © 2021 NCQA. All Rights Reserved.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004-2021 American Medical Association. LOINC® copyright 2004-2021 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2021 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2021 World Health Organization. All Rights Reserved.
Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.
Positive microalbuminuria test result documented and reviewed

Yes

Positive macroalbuminuria test result documented and reviewed

Yes

Data Completeness Met + Performance Met
3060F or equivalent (10 patients)

No

Negative microalbuminuria test result documented and reviewed

Yes

Data Completeness Met + Performance Met
3061F or equivalent (10 patients)

No

Positive macroalbuminuria test result documented and reviewed

Yes

Data Completeness Met + Performance Met
3062F or equivalent (10 patients)

No

Documentation of treatment for nephropathy

Yes

Data Completeness Met + Performance Met
3066F or equivalent (10 patients)

No

Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy

Yes

Data Completeness Met + Performance Met
G8506 or equivalent (0 patients)

No

Nephropathy screening was not performed, reason not otherwise specified

Yes

Data Completeness Not Met
Quality Data Code or equivalent not submitted (10 Patients)

No
**SAMPLE CALCULATIONS:**

<table>
<thead>
<tr>
<th>Calculation</th>
<th>Formula</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Completeness</td>
<td>Performance Met ($a_1^a + a_2^a + a_3^a + a_4^a = 40$ patients) + Performance Not Met ($c = 30$ patients) / Eligible Population / Denominator ($d = 80$ patients)</td>
<td>70 patients = 87.50%</td>
</tr>
<tr>
<td>Performance Rate</td>
<td>Performance Met ($a_1^a + a_2^a + a_3^a + a_4^a = 40$ patients) / Data Completeness Numerator ($70$ patients)</td>
<td>40 patients = 57.14%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>70 patients</td>
</tr>
</tbody>
</table>

*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

CPT only copyright 2021 American Medical Association. All rights reserved.

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.
Start with Denominator

2. Check Patients aged 18 years to 75 years on date of encounter:
   a. If Patients aged 18 years to 75 years on date of encounter equals No, do not include in Eligible Population/Denominator. Stop processing.
   b. If Patients aged 18 years to 75 years on date of encounter equals Yes, proceed to Diagnosis for diabetes as listed in Denominator*.

3. Check Diagnosis for diabetes as listed in Denominator*:
   a. If Diagnosis for diabetes as listed in Denominator* equals No, do not include in Eligible Population/Denominator. Stop processing.
   b. If Diagnosis for diabetes as listed in Denominator* equals Yes, proceed to Patient encounter during the performance period as listed in Denominator*.

4. Check Patient encounter during the performance period as listed in Denominator*:
   a. If Patient encounter during the performance period as listed in Denominator* equals No, do not include in Eligible Population/Denominator. Stop processing.
   b. If Patient encounter during the performance period as listed in Denominator* equals Yes, proceed to Patients who use hospice services any time during the measurement period.

5. Check Patients who use hospice services any time during the measurement period:
   a. If Patients who use hospice services any time during the measurement period equals Yes, do not include in Eligible Population/Denominator. Stop processing.
   b. If Patients who use hospice services any time during the measurement period equals No, proceed to Patients who use palliative care services any time during the measurement period.

6. Check Patients who use palliative care services any time during the measurement period:
   a. If Patients who use palliative care services any time during the measurement period equals Yes, do not include in Eligible Population/Denominator. Stop processing.
   b. If Patients who use palliative care services any time during the measurement period equals No, proceed to Patient age greater than or equal to 66 in Institutional Special Needs Plans (SNP) or residing in long-term care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period.

7. Check Patient age greater than or equal to 66 in Institutional Special Needs Plans (SNP) or residing in long-term care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period:
   a. If Patient age greater than or equal to 66 in Institutional Special Needs Plans (SNP) or residing in long-term care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period equals Yes, do not include in Eligible Population/Denominator. Stop processing.
   b. If Patient age greater than or equal to 66 in Institutional Special Needs Plans (SNP) or residing in long-term care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period equals No, proceed to Patients who use palliative care services any time during the measurement period.
care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period equals No, proceed to Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or year prior to measurement period.

8. Check Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or year prior to measurement period:
   a. If Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or year prior to measurement period equals Yes, do not include in Eligible Population/Denominator. Stop processing.
   b. If Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or year prior to measurement period equals No, proceed to Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period.

9. Check Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period:
   a. If Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period equals Yes, do not include in Eligible Population/Denominator. Stop processing.
   b. If Patients age greater than or equal to 66 with at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period equals No, include in Eligible Population/Denominator.

10. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.

11. Start Numerator

12. Check Positive microalbuminuria test result documented and reviewed:
   a. If Positive microalbuminuria test result documented and reviewed equals Yes, include in Data Completeness Met and Performance Met.
      • Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 10 patients in the Sample Calculation.
   b. If Positive microalbuminuria test result documented and reviewed equals No, proceed to Negative microalbuminuria test result documented and reviewed.
13. Check **Negative microalbuminuria test result documented and reviewed**:
   a. If **Negative microalbuminuria test result documented and reviewed** equals Yes, include in **Data Completeness Met and Performance Met**.
      - **Data Completeness Met and Performance Met** letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a² equals 10 patients in the Sample Calculation.
   b. If **Negative microalbuminuria test result documented and reviewed** equals No, proceed to **Positive macroalbuminuria test result documented and reviewed**.

14. Check **Positive macroalbuminuria test result documented and reviewed**:
   a. If **Positive macroalbuminuria test result documented and reviewed** equals Yes, include in **Data Completeness Met and Performance Met**.
      - **Data Completeness Met and Performance Met** letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a³ equals 10 patients in the Sample Calculation.
   b. If **Positive macroalbuminuria test result documented and reviewed** equals No, proceed to **Documentation of treatment for nephropathy**.

15. Check **Documentation of treatment for nephropathy**:
   a. If **Documentation of treatment for nephropathy** equals Yes, include in the **Data Completeness Met and Performance Met**.
      - **Data Completeness Met and Performance Met** letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a⁴ equals 10 patients in the Sample Calculation.
   b. If **Documentation of treatment for nephropathy** equals No, proceed to **Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy**.

16. Check **Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy**:
   a. If **Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy** equals Yes, include in the **Data Completeness Met and Performance Met**.
      - **Data Completeness Met and Performance Met** letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a⁵ equals 0 patients in the Sample Calculation.
   b. If **Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy** equals No, proceed to **Nephropathy screening was not performed, reason not otherwise specified**.

17. Check **Nephropathy screening was not performed, reason not otherwise specified**:
   a. If **Nephropathy screening was not performed, reason not otherwise specified** equals Yes, include in the **Data Completeness Met and Performance Not Met**.
      - **Data Completeness Met and Performance Not Met** letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 30 patients in the Sample Calculation.
b. If Nephropathy screening was not performed, reason not otherwise specified equals No, proceed to Data Completeness Not Met.

18. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

Sample Calculations:
Data Completeness equals Performance Met (a₁ plus a² plus a³ plus a⁴ plus a⁵ equals 40 patients) plus Performance Not Met (c equals 30 patients) divided by Eligible Population / Denominator (d equals 80 patients). All equals 70 patients divided by 80 patients. All equals 87.50 percent.

Performance Rate equals Performance Met (a₁ plus a² plus a³ plus a⁴ plus a⁵ equals 40 patients) divided by Data Completeness Numerator (70 patients). All equals 40 patients divided by 70 patients. All equals 57.14 percent.

*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.